Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
CD70
Introduction
CD70 (Cluster of Differentiation 70) is a ligand for CD27.
Clinical significance
Clinical significance
The CD70 protein is expressed on highly activated lymphocytes (like in T- and B-cell lymphomas). It is therefore suggested that anti-CD70 antibodies might be a possible treatment for CD70 positive lymphomas as normal lymphocytes have low CD70 expression.[1]
Drug development
Drug development
ARGX-110 is a CD70-specific antibody that is currently under investigation for the treatment of hematological malignancies. It is being developed by the Belgian company arGEN-X. In December 2013 a first part of a phase 1b trial was completed. In January 2014 a safety and efficacy phase of the study started.[2]
Vorsetuzumab mafodotin is a CD70-targeted antibody-drug conjugate that started clinical trials for renal cell carcinoma.[3]
References
References
- ↑ Israel BF, Gulley M, Elmore S, Ferrini S, Feng WH, Kenney SC (2005). “Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas”. Mol. Cancer Ther. 4 (12): 2037–44. doi:10.1158/1535-7163.MCT-05-0253. PMID 16373719.
- ↑ “ARGX-110: first-in-class CD70-targeting antibody with unique mode of therapeutic action”. arGEN-X. Retrieved 28 February 2015.
- ↑ Seattle Genetics Third Quarter 2013 Financial Report
External links
External links
- CD70+Antigens at the US National Library of Medicine Medical Subject Headings (MeSH)